Migraine drug developer Klaria Pharma posts Q4 loss per share of 0.03 SEK

Klaria Pharma Holding AB (publ)

20/02/2026 15:13

Adds 'mln' to clarify unit in Overview and Result Drivers sections

Overview

Swedish pharmaceutical firm's Q4 net sales at 0 SEK

Q4 EPS at -0.03 SEK

Company received 31.6 mln SEK from share issue in July

Outlook

Klaria did not provide specific guidance for future financial metrics

Result Drivers

REDUCED R&D EXPENSES - Klaria reported lower R&D expenses in Q4, amounting to 4.8 mln SEK compared to 9.3 mln SEK in the previous year

CAPITAL RAISED - Klaria raised 31.6 mln SEK from a share issue in July, providing funds for operations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 0
Q4 EPS
-SEK 0.03


Analyst Coverage

Wall Street's median 12-month price target for Klaria Pharma Holding AB (publ) is SEK0.97, about 25.9% above its February 19 closing price of SEK0.77

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nWkrcmz78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)